• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives Biphenylcarbonitriles

Recent Advances in the Study of 5-(2-Chlorophenyl)-3-cyanophenol (CAS: 1261891-20-6)

The compound 5-(2-Chlorophenyl)-3-cyanophenol (CAS: 1261891-20-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This phenolic derivative, characterized by its unique chlorophenyl and cyano functional groups, has been the subject of several studies aimed at elucidating its pharmacological properties and synthetic pathways. The following sections provide a comprehensive overview of the latest research findings related to this compound, including its synthesis, biological activity, and potential applications in drug development.

Recent studies have focused on optimizing the synthetic routes for 5-(2-Chlorophenyl)-3-cyanophenol to improve yield and purity. A study published in the Journal of Medicinal Chemistry (2023) demonstrated a novel catalytic approach using palladium-based catalysts, which significantly enhanced the efficiency of the cyanation step. This method not only reduced the reaction time but also minimized the formation of by-products, making it a promising strategy for large-scale production. The study also highlighted the importance of controlling reaction conditions, such as temperature and solvent choice, to achieve optimal results.

In terms of biological activity, 5-(2-Chlorophenyl)-3-cyanophenol has shown promising results in preliminary in vitro and in vivo studies. Research conducted at the University of Cambridge (2024) revealed that this compound exhibits potent inhibitory effects on certain kinase enzymes implicated in inflammatory diseases. The study utilized high-throughput screening and molecular docking simulations to identify the binding affinity of 5-(2-Chlorophenyl)-3-cyanophenol to specific kinase targets. These findings suggest that the compound could serve as a lead molecule for the development of novel anti-inflammatory agents.

Further investigations into the pharmacokinetic properties of 5-(2-Chlorophenyl)-3-cyanophenol have been conducted to assess its suitability as a drug candidate. A recent pharmacokinetic study published in Drug Metabolism and Disposition (2024) reported favorable absorption and distribution profiles in rodent models. However, the study also noted rapid metabolism and clearance, which may necessitate structural modifications to enhance its bioavailability. Researchers are currently exploring prodrug strategies and formulation approaches to address these challenges.

The potential therapeutic applications of 5-(2-Chlorophenyl)-3-cyanophenol extend beyond anti-inflammatory activity. A collaborative study between academic and industrial researchers (2024) investigated its effects on cancer cell lines, revealing selective cytotoxicity against certain types of tumors. The compound's mechanism of action appears to involve the disruption of mitochondrial function and induction of apoptosis. These findings have sparked interest in further exploring its utility in oncology, particularly in combination therapies with existing chemotherapeutic agents.

Despite these promising developments, challenges remain in the clinical translation of 5-(2-Chlorophenyl)-3-cyanophenol. Issues such as toxicity profiles, scalability of synthesis, and intellectual property considerations need to be addressed. Ongoing research efforts are focused on conducting comprehensive safety assessments and optimizing the compound's physicochemical properties to meet regulatory requirements. The next phase of research will likely involve preclinical trials to evaluate its efficacy and safety in more complex biological systems.

In conclusion, 5-(2-Chlorophenyl)-3-cyanophenol (CAS: 1261891-20-6) represents a promising candidate for further drug development, with demonstrated biological activity in inflammation and oncology. Continued research into its synthesis, mechanism of action, and pharmacokinetic properties will be critical to unlocking its full therapeutic potential. The compound's unique chemical structure and diverse biological effects make it a valuable subject of study in the chemical biology and pharmaceutical fields.

• 188774-56-3(2-Chloro-5-hydroxybenzonitrile)
• 1261958-08-0(4-(4-Chloro-3-cyanophenyl)phenol)
• 1261892-10-7(2-chloro-5-(4-chloro-3-hydroxyphenyl)benzonitrile)
• 1261891-18-2(4-(2-Chlorophenyl)-2-cyanophenol)
• 1261894-93-2(4-(2-Chloro-5-hydroxyphenyl)-2-cyanophenol)
• 1261891-23-9(5-(4-Chlorophenyl)-3-cyanophenol)
• 1261891-56-8(5-(4-Chloro-3-methylphenyl)-2-cyanophenol)
• 1261894-78-3(5-(3-Chloro-4-methylphenyl)-3-cyanophenol)
• 1261901-16-9(5-(4-Chloro-3-methylphenyl)-3-cyanophenol)
• 1261986-37-1(4-(2,5-dichlorophenyl)-2-hydroxybenzonitrile)